Socioeconomic impact of diabetic nephropathy: Can we improve the outcome?

Journal of Hypertension, Supplement

Volumn 15, Issue 2, 1997, Pages

  Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enyme inhibitors; Calcium antagonists; Diabetes; Economics; Nephropathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DIALYSIS; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN RESTRICTION; SOCIOECONOMICS; SODIUM RESTRICTION; TIME; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; COST OF ILLNESS; DIABETIC NEPHROPATHIES; DIRECT SERVICE COSTS; HUMANS; QUALITY OF LIFE;

EID: 0030898203     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Barnett AH: Diabetes and hypertension. Br Med Bull 1994, 50:397-407.
2. Nelson RG, Knowler WC, Pettit DJ, Bennett PH: Kidney diseases in diabetes. In Diabetes in America. Bethesda: National Institutes of Health Publ 95-1468; 1995:349-400.
3. Bolger PG, Davies R: Simulation model for planning renal services in a district health authority. BMJ 1992, 305:605-608.
4. Port FK: End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions. Kidney Int 1995, 48 (suppl 50): S3-S6.
5. Leese B: The costs of diabetes and its complications. Soc Sci Med 1992, 35:1303-1310.